Raghav Krishnapriyan
Partner
San Francisco
Raghav is an IP litigator, with a focus on high-stakes patent litigation.
Raghav has litigated a broad range of technology, life sciences, and trade secret cases through trial and appeal. In the life sciences space, he helped secure a $178 million patent infringement verdict for a Bay Area pharmaceutical client, was instrumental in obtaining a highly favorable settlement in a complex contract case involving CAR-T technology, and fended off IPRs filed against foundational fusion protein technology by biosimilar makers. In the technology space, his facility with both web programming and legal minutiae has resulted in victories in a bet-the-company trade secret litigation against a startup revolutionizing scientific research, summary judgment in an action against his client involving five widely-litigated web patents, and a judgment of patent invalidity under § 101 against seven patents. He has also litigated class actions and criminal cases that have a technology-related focus. He has assisted numerous emerging and venture-funded companies across industry sectors.
Raghav also maintains an active pro bono practice, representing asylum seekers and inmates seeking compassionate release.
Raghav holds a bachelor’s degree in chemistry from the University of California, Davis, and a J.D. from the University of California, Berkeley. He clerked for the Honorable James Donato of the United States District Court for the Northern District of California and the Honorable Jane Kelly of the United States Court of Appeals for the Eighth Circuit.
-
- Helped secure a $178 million patent infringement trial verdict for a Bay Area drug development company against a major multinational.
- Removed company-threatening trade secret case against startup to federal court and successfully compelled arbitration in case involving numerous legal issues of first impression, resulting in a walkaway.
- Secured summary judgment of noninfringement in case involving widely-asserted web patents.
- Defeated institution of inter partes review challenging patents protecting revolutionary anti-VEGF drugs.
